Invest in Joint Support for Humans & Pets with a unique ingredient

Univestin® is a unique and natural, plant-based formula designed for humans that is clinically proven to provide fast relief from joint discomfort. Containing two primary actives – baicalin and catechins – this botanical combination was screened from over 1230 medicinal plants, using Unigen’s PhytoLogix®.

Mirroring trends in the human personal wellness sector, the pet-health market shows significant growth. This opens avenues for companies to diversify into pet health, potentially by introducing a valuable product like Anivestin™ to their product line! Anivestin™ features the same plant-based composition, but is tailored to alleviate joint discomfort in animals while also promoting oral health. Research has demonstrated that these two extracts work synergistically in-vivo to produce an analgesic and anti-inflammatory effect, with regards to both onset and duration.

Univestin® for Humans

Two separate human clinical trials demonstrated Univestin®'s efficacy in addressing osteoarthritis (OA) symptoms. A 2011 Florida State University study¹ involving 80 subjects found that a 1-week supplementation of 500 mg/day Univestin® was superior to a 440 mg/day NSAID in reducing discomfort (WOMAC scale) and stiffness, while also improving range of motion. Another 2003 study by JSS Medical Research Inc.² with 60 subjects suffering from rheumatoid arthritis or OA showed that Univestin® (at 250 mg/day and 500 mg/day) was significantly more effective than the NSAID option (200 mg/day) in reducing joint stiffness and functional incapacity within 30 days, with the 500 mg/day dose also being more effective for discomfort reduction.

Anivestin™ for Pets

Clinical trials in dogs have demonstrated Anivestin™’s efficacy in treating both osteoarthritis (OA) pain and periodontal disease. In a two-month OA study³, Anivestin™ (FlexileRx) significantly outperformed CosequinDS in reducing pain scores, demonstrating that it could be twice as effective and whilst also being fast-acting with generally mild adverse events. Similarly, in a 12-week study on beagle dogs⁴ with induced periodontal disease, dietary Anivestin™ (at 0.1% and 0.2%) resulted in statistically significant reductions in key clinical indices like gingivitis, pocket depth, and gum bleeding, with the 0.2% dose showing greater improvements in gingival indices than doxycycline, suggesting its potential for managing these common conditions in companion animals.

Discover much more about these pioneering solutions for both humans and companion animals by downloading our Univestin® and Anivestin™ product profile sheets or by contacting the team!

_{References
(1) Tiku M.L., et al (1999) Aggrecan degradation in chondrocytes is mediated by reactive oxygen species and protected by antioxidants.
(2) Sampalis J., et al. (2012) A randomized, double blind, placebo and active comparator controlled pilot study of UP446, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin.
(3) Burnett BP, Stenstrom KK, Baarsch MJ, et. al. “A Flavonoid Mixture, Dual Inhibitor of Cyclooxygenase and 5-Lipoxygenase Enzymes Shows Superiority to Glucosamine/Chondroitin for Pain Management in Moderate Osteoarthritic Dogs.” International Journal of Applied Research 7.1&2 (2009): 1-12.
(4) Yimam M, Brownell L, Do SG, Lee YC, Kim DS, Seo K, Jeong M, Kim S, Jia Q. Protective Effect of UP446 on Ligature-Induced Periodontitis in Beagle Dogs. Dent J (Basel). 2019 Mar 28;7(2):33}